LLG783

LLG783 is a monoclonal antibody developed by Novartis for the treatment of peripheral artery disease (PAD) and intermittent claudication. It acts as an LDL receptor antagonist. The drug was investigated in clinical trials to assess its safety, tolerability, pharmacokinetics, and efficacy in improving walking distance and pain-free walking distance in patients with PAD. In these studies, LLG783 was administered intravenously once every four weeks for a total of four doses over 12 weeks. While the drug was found to be safe and well-tolerated, it did not demonstrate significant improvement over placebo in functional outcomes such as maximum walking distance or pain-free walking distance[1][3][5].